Recently Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib showed promising therapeutic effect in relapsed/refractory CLL and B-cell NHL, which provided essential alternatives for these patients. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.